Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
119M
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
109M
-
Shares change
-
+21.9M
-
Total reported value, excl. options
-
$1.08B
-
Value change
-
+$267M
-
Put/Call ratio
-
5.99
-
Number of buys
-
81
-
Number of sells
-
-54
-
Price
-
$9.91
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) as of Q1 2024
152 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2024.
Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 109M shares
of 119M outstanding shares and own 91.74% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (8.79M shares), STATE STREET CORP (8.78M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (7.88M shares), Rubric Capital Management LP (7.51M shares), Polar Capital Holdings Plc (6.89M shares), BlackRock Inc. (6.66M shares), VANGUARD GROUP INC (5.17M shares), FRANKLIN RESOURCES INC (4.64M shares), GILDER GAGNON HOWE & CO LLC (4.23M shares), and MORGAN STANLEY (4.01M shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.